Kiora Pharmaceuticals Inc
KPRX
查看详细走势图
2.050USD
-0.070-3.30%
收盘 12/24, 13:00（美东）报价延迟15分钟
7.04M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.30%
5天
0.00%
1月
+12.64%
6月
-33.22%
今年开始到现在
-37.88%
1年
-37.69%
查看详细走势图
TradingKey Kiora Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
Kiora Pharmaceuticals Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名181/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价12.00。中期看，股价处于下降通道。近一个月，市场表现较强，基本面评分较高，但较强的走势得没有得到技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Kiora Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
买入
评级
12.000
目标均价
+479.71%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Kiora Pharmaceuticals Inc亮点
亮点风险
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
业绩增长期
公司处于发展阶段，最新年度总收入16.02M美元
业绩转盈
公司业绩转盈，最新年度盈利美元
估值低估
公司最新PE估值-0.94，处于3年历史低位
机构减仓
最新机构持股724.05K股，环比减少58.37%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值20.91K
Kiora Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Kiora Pharmaceuticals Inc简介
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
公司代码KPRX
公司Kiora Pharmaceuticals Inc
CEOStrem (Brian M)
网址https://kiorapharma.com/
常见问题
Kiora Pharmaceuticals Inc(KPRX)的当前股价是多少？
Kiora Pharmaceuticals Inc(KPRX)的当前股价是 2.050。
Kiora Pharmaceuticals Inc的股票代码是什么？
Kiora Pharmaceuticals Inc的股票代码是KPRX。
Kiora Pharmaceuticals Inc股票的52周最高点是多少？
Kiora Pharmaceuticals Inc股票的52周最高点是4.180。
Kiora Pharmaceuticals Inc股票的52周最低点是多少？
Kiora Pharmaceuticals Inc股票的52周最低点是1.764。
Kiora Pharmaceuticals Inc的市值是多少？
Kiora Pharmaceuticals Inc的市值是7.04M。
Kiora Pharmaceuticals Inc的净利润是多少？
Kiora Pharmaceuticals Inc的净利润为3.59M。
现在Kiora Pharmaceuticals Inc(KPRX)的股票是买入、持有还是卖出？
根据分析师评级，Kiora Pharmaceuticals Inc(KPRX)的总体评级为买入，目标价格为12.000。
Kiora Pharmaceuticals Inc(KPRX)股票的每股收益（EPS TTM）是多少
Kiora Pharmaceuticals Inc(KPRX)股票的每股收益（EPS TTM）是-2.189。
相关品种
